European Expert Consortium to Develop a Novel Pandemic Flu Vaccine - - BioPharm International

ADVERTISEMENT

European Expert Consortium to Develop a Novel Pandemic Flu Vaccine

BioPharm Bulletin

Five European organizations, including three companies and two hospitals, have joined forces to develop a novel pandemic influenza vaccine as a potential emergency vaccination.

The four-year FluVac project, as it will be called, has been awarded a grant of €3.5 million from the European Union to help fund the research and the development of a new vaccine. Nobilon International BV will coordinate the project. The FluVac project consortium consists of Nobilon International BV (Boxmeer, the Netherlands), Protherics PLC (Cheshire, UK), Retroscreen Virology Ltd (London, UK), Erasmus Medical Centre (Rotterdam, the Netherlands), and Landspitali University Hospital (Reykjavik, Iceland).

Nobilon release

blog comments powered by Disqus

ADVERTISEMENT

ADVERTISEMENT

Novartis Reports Positive Results for Secukinumab in Ankylosing Spondylitis Trials
October 23, 2014
Pall ForteBio Releases Bioprocessing Contamination Detection Kit
October 22, 2014
Roche to Expand and Improve its Basel Site
October 22, 2014
FDA Panel Unanimously Backs Secukinumab for the Treatment of Psoriasis
October 22, 2014
EMA Works to Speed Up Ebola Treatment
October 20, 2014
Author Guidelines
Source: BioPharm Bulletin,
Click here